CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's senior management team will conduct a fireside chat on Tuesday, April 8, 2025, at 12:45 p.m. ET.
The presentation will be accessible through a live webcast on the company's investor relations website under the 'Events & Presentations' section. Interested parties can access the replay of the webcast, which will remain available for 14 days after the presentation.
CRISPR Therapeutics (NASDAQ: CRSP), un'azienda biofarmaceutica specializzata in medicinali basati sui geni, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. Il team di gestione senior dell'azienda condurrà una chiacchierata informale martedì 8 aprile 2025, alle 12:45 p.m. ET.
La presentazione sarà accessibile tramite un webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, nella sezione 'Eventi e Presentazioni'. Le parti interessate possono accedere alla registrazione del webcast, che rimarrà disponibile per 14 giorni dopo la presentazione.
CRISPR Therapeutics (NASDAQ: CRSP), una compañía biofarmacéutica especializada en medicamentos basados en genes, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham. El equipo de alta dirección de la compañía realizará una charla informal el martes 8 de abril de 2025, a las 12:45 p.m. ET.
La presentación será accesible a través de una transmisión en vivo en el sitio web de relaciones con inversionistas de la compañía en la sección 'Eventos y Presentaciones'. Las partes interesadas pueden acceder a la repetición de la transmisión, que estará disponible durante 14 días después de la presentación.
CRISPR Therapeutics (NASDAQ: CRSP), 유전자 기반 의약품을 전문으로 하는 생명공학 회사가 제24회 니드햄 연례 가상 의료 회의에 참여한다고 발표했습니다. 회사의 고위 경영진 팀은 2025년 4월 8일 화요일 오후 12시 45분 ET에 화상 대화를 진행할 예정입니다.
발표는 회사의 투자자 관계 웹사이트 '이벤트 및 발표' 섹션을 통해 실시간 웹캐스트로 접근할 수 있습니다. 관심 있는 분들은 발표 후 14일 동안 제공되는 웹캐스트의 재생을 이용할 수 있습니다.
CRISPR Therapeutics (NASDAQ: CRSP), une entreprise biopharmaceutique spécialisée dans les médicaments basés sur les gènes, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. L'équipe de direction senior de l'entreprise animera une discussion informelle mardi 8 avril 2025, à 12h45 ET.
La présentation sera accessible via un webinaire en direct sur le site Web des relations investisseurs de l'entreprise dans la section 'Événements & Présentations'. Les parties intéressées peuvent accéder à la rediffusion du webinaire, qui restera disponible pendant 14 jours après la présentation.
CRISPR Therapeutics (NASDAQ: CRSP), ein biopharmazeutisches Unternehmen, das sich auf gentherapeutische Medikamente spezialisiert hat, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Das Senior Management-Team des Unternehmens wird am Dienstag, den 8. April 2025, um 12:45 Uhr ET ein informelles Gespräch führen.
Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens im Abschnitt 'Veranstaltungen & Präsentationen' zugänglich sein. Interessierte Parteien können auf die Wiederholung des Webcasts zugreifen, die 14 Tage nach der Präsentation verfügbar bleibt.
- None.
- None.
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Needham Healthcare Conference 2025?
How can investors watch CRSP's Needham Conference presentation?
How long will CRSP's Needham Conference presentation replay be available?
What type of presentation will CRSP deliver at the Needham Healthcare Conference?
